Saltar al contenido
Merck
Todas las fotos(2)

Key Documents

View All Documentation

GF35079554

Lanthanum

foil, not light tested, 50x50mm, thickness 0.025mm, as rolled, 99%

Sinónimos:

Lanthanum, LA000200

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Fórmula empírica (notación de Hill):
La
Número de CAS:
7439-91-0
Peso molecular:
138.91
MDL number:
MFCD00011066
UNSPSC Code:
12141607
PubChem Substance ID:
329805327
NACRES:
NA.23

assay

99%

form

foil

manufacturer/tradename

Goodfellow 350-795-54

resistivity

54 μΩ-cm

size × thickness

50x50 mm × 0.025 mm

bp

3464 °C (lit.)

mp

920 °C (lit.)

density

6.19 g/mL at 25 °C (lit.)

SMILES string

[La]

InChI

1S/La

InChI key

FZLIPJUXYLNCLC-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow

Storage Class

4.3 - Hazardous materials which set free flammable gases upon contact with water

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Stuart M Sprague
Current medical research and opinion, 23(12), 3167-3175 (2007-11-10)
Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate. A literature search was performed
Tilman B Drüeke
Seminars in dialysis, 20(4), 329-332 (2007-07-20)
Controlling serum phosphorus levels in patients with renal failure is critical. The use of oral phosphate-binding agents is universal for patients with end-stage kidney disease to reduce phosphate absorption. The therapeutic goal is to reduce serum phosphorus levels without disturbing
Gadolinium and lanthanum: a iatrogenic transmetallation?
Simona Brambilla et al.
Clinical biochemistry, 41(13), 1029-1033 (2008-06-19)
Stephen J P Damment et al.
Clinical pharmacokinetics, 47(9), 553-563 (2008-08-14)
Lanthanum carbonate is considered to be the most potent of a new generation of noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease (CKD), a condition associated with progressive bone and cardiovascular pathology and a markedly elevated risk
Amy Barton Pai et al.
Expert opinion on drug metabolism & toxicology, 5(1), 71-81 (2009-02-25)
Hyperphosphatemia is recognized as a principal mineral disorder in chronic kidney disease (CKD) that leads to the development of secondary hyperparathyroidism. Recent data indicate that hyperphosphatemia is associated with accelerated cardiac calcification and increased mortality in patients with CKD. Control
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico